Role of CRH in colitis and colitis-associated cancer: a combinative result of central and peripheral effects?

1 Introduction

Ulcerative colitis (UC) and Crohn’s disease, the common chronic inflammation in the gastrointestinal system, are the two main forms of inflammatory bowel disease (IBD) (1, 2). The precise cause of IBD is not thoroughly known yet. It is observed that UC patients may have a dysregulated mucosal immune response to commensal gut flora, resulting in bowel inflammation characteristically restricted to the mucosal surface in the colon (3, 4). Chronic inflammation is fundamentally an immune response, which provides microenvironment for tumorigenesis and accounts for a big portion of cancer-causing factors (4), which is in concert with the case between colitis and colorectal cancer (CRC) (5, 6), although meta-analysis does not show an increased CRC risk over time of inflammation (7). CRC is one of the most common forms of malignant tumor worldwide, and patients with UC are at higher risk for developing CRC, i.e., colitis-associated colon cancer (CAC), than the general population (8). Therefore, anti-inflammation treatment is likely a useful approach for preventing the occurrence of CAC (9). However, despite constant studies and advances in conventional and/or targeted therapy, the survival rate of CRC patients is still not very high (10, 11).

Corticotropin-releasing factor family peptides (CRF peptides) include 4 members, corticotropin releasing hormone (CRH), urocortin (UCN1), UCN2 and UCN3, mediating their effects via two distinct CRF receptor subtypes, CRF1 and CRF2, with CRH being the selective agonist of CRF1, UCN1 of both, and UCN2-3 of CRF2 (12–18) (Table 1).

Table 1 Corticotropin-releasing family peptides (CRF peptides) and receptors.

Both CRF1 and CRF2 belong to the seven transmembrane domain family positively coupled to adenylate cyclase via G proteins (13–15). CRH, a 41-amino acid peptide, is observed to activate cAMP/MAPK pathway via CRF1 (19, 20). It is recognized as a primary regulator of the hypothalamic pituitary axis (HPA axis) (17, 21–23). The paraventricular nucleus (PVN) of the hypothalamus is the main source for CRH in the brain (17). CRH, UCNs and the two receptors are also reported to express widely in peripheral cells/tissues, being recognized as important cardiovascular peptides and immune/inflammatory molecules (23–28). Their presence in gastrointestinal system has been detected for a long time since decades ago (29–31). Moreover, CRH and UCN3 are detected in the human colon (32) and UCN1 mRNA is observed in the rat enteric nervous system (33). CRF1 and CRF2 are encoded by specific genes (13). CRF1 is the main type of receptor in the brain (13) while it is also abundant in some peripheral cells/tissues including skin, inflammatory cells and gastrointestinal system (13, 28, 30, 34). And CRF2α is predominantly found in neurons and CRF2β in both brain and peripheral tissues including cardiac & skeletal muscle and the gastrointestinal tract (13, 35, 36). Both CRF1 and CRF2 are distributed within the rat colon: CRF1 is found in the colonic crypts, the surface epithelium, and the lamina propria of the proximal colonic mucosa. CRF1 expression is also detected in the myenteric and submucosal nervous plexus. CRF2 expression is found to be localized mainly in the luminal surface of the crypts and in blood vessels of the submucosal layer (31). Also in the human colonic mucosa, both CRF1 and CRF2 mRNA are detected in lamina propria mononuclear cells (30). These results support a role for the two receptors’ involvement in regulating peripheral colonic effects of CRH and UCNs. Since this review focuses on the selective CRF1 agonist, CRH, more about CRH/CRF1 effects will be discussed.

The hypothalamus-pituitary-adrenal (HPA) axis, functionally a hormone stimulating cascade, mainly CRH-adrenocorticotropin (ACTH)-cortisol axis, is a critical element for stress response and immune/inflammatory processes (37). Chronic stress, characterized by activation of HPA axis and sympathetic nervous system, has been reported to be an important reason in the development of inflammation and tumorigenesis (38–40), suggesting that CRH indirectly participate in inflammation and tumorigenesis via HPA axis as a centrally active molecule. Furthermore, HPA axis communicates with the immune system at multiple levels (41, 42). Bidirectional interactions between HPA and immunity contribute to their role in inflammation and cancers: HPA activation results in secretion of CRH, ACTH and cortisol modulating the immune response while immunity-related substances, such as interleukin-1 (IL-1), IL-6 and tumor necrosis factor alpha (TNF-α) can backwards stimulate the HPA axis (42). In addition, relationship between gut microbiome and the brain, i.e. brain-gut-microbiota axis, has attracted much attention for its complicated part in stress and IBD (43–45). The imbalance of brain-gut-microbiota axis also leads to dysregulation of the HPA axis (44). Therefore, it is reasonable that CRH, as the major mediator of stress response, may take a part in IBD and CRC via brain-gut-microbiota axis. Taken together, CRH is suggested to take part in colonic inflammation and inflammation-based tumorigenesis indirectly via HPA axis and brain-gut-microbiota axis.

Moreover, peripherally direct participation of CRH in colonic inflammation has been well proved (46, 47). The expression of CRH in the large bowel of patients with UC is found considerably enhanced in mucosal inflammatory cells and slightly increased in colonic mucosal epithelial cells, suggesting CRH’s role via modulating intestinal immune/inflammatory system in UC (47). Also, it is reported that CRH may induce intestinal hyperpermeability in human colon mucosa via mast cells (48). We and others have also reported the direct peripheral role of CRH/UCNs & receptors in immunity/inflammation and cancers (42, 49–54), including colitis and colitis-associated colon cancer (CAC) (55–58).

In summary, over recent decades, CRF peptides and receptors have been found to be significantly correlated with the bowel inflammation and the development of CAC. However, controversies over the origin of CRH action sites have always been existing. Up-to-date, taken together, it is understandable that CRH, as both a centrally active endocrine hormone and peripherally active peptide, may play an important role in colitis and CAC via both indirect actions regulating chronic stress and direct peripheral effects, although there still lack experimental evidences showing direct relationship between central CRH effect and colitis/CAC and only a few investigations show the direct peripheral effects of CRH on CAC.

2 The central role of CRH in colitis and CAC

Stress, inflammation and colon cancer are highly related, forming a CRH-system driven crosstalk (38). Therefore, there may not be an absolute clearcut between the central and peripheral effects of CRH on inflammation and cancer. Up to date, little evidence has suggested a direct relationship between central CRH and the development of colitis and CAC. Instead, the central role of CRH in inflammation and cancers is mainly thought to be via mediating HPA axis as a stress mediator (38, 59, 60). Under chronic stress, the HPA axis is activated and the release of CRH from the PVN of the hypothalamus at its nerve endings in eminence, which is carried to the pituitary gland through the portal vessel, stimulating the secretion of ACTH, which in turn stimulates the secretion of cortisol from the adrenal gland. The hypothalamus-released CRH acts on CRF1 in the pituitary gland, causing ACTH release from the anterior pituitary (13, 61). About half of CRH in the brain is found to be bound with CRH binding protein (CRH-BP). In exposure to stress, the expression of CRH-BP increases in a time-dependent fashion, likely being a negative feedback mechanism for CRH’s action on CRF1 (62).

2.1 Central role of CRH/CRF1 in colitis

There exist contrary reports about CRH’s role in colitis. As summarized in the following, some researchers observe no effect or anti-inflammatory effect while many others find its pro-inflammatory actions in colitis.

2.1.1 The non-proinflammatory/anti-inflammatory role of central CRH in colitis

CRH is a 41-amino acid peptide, a primary regulator of the HPA axis and a coordinator of the gastrointestinal response to stress (22, 63, 64). The most important effect of central CRH/CRF1 is to stimulate the pituitary gland to release ACTH causing cortisol secretion of from the adrenal gland cortex, i.e., mediating the function of HPA axis (61). Since cortisol is an anti-inflammatory hormone, CRH is normally recognized to act in an anti-inflammatory fashion. However, only a few reports present consistent evidences in case of colitis. While acute colonic inflammation induced CRH secretion from PVN in the hypothalamus, CRH level is found to remain at a high level in the brain after the recovery of colitis (65), suggesting a weak link between central CRH effect and colitis. On the other hand, Gue et al. find that centrally injected CRH may have complicated influences on colitis (66). By evaluating the influence of stress and the involvement of CRH on experimental colitis in rats, it is observed that centrally injected CRH antagonist, alpha-helical CRH-(9-41) has no effect on trinitrobenzenesulfonic acid-induced colitis but enhances the effects of stress on colitis, suggesting that central CRH may only participate in controlling the process of colitis in case of stress (66). Moreover, Million et al. observe a protective role of brain CRH from stress-induced worsening of colitis (67). They assess the role of central CRH in stress-induced worsening of colitis in inbred rat strains with hypo (Lewis) and hyper (Fischer344) CRH responses to stress. It is observed that trinitrobenzenesulfonic acid induces colitis with similar severity in both strains, which is inhibited by central injection of CRH. Chronic stress aggravates colitis more in Lewis than Fischer rats, which is reversed by central injection of the CRH antagonist astressin, indicating that central CRH restrains the stress’ proinflammatory action in experimental colitis (67). Similarly, it is reported that central CRH inhibits gastric motility, which can also be abolished by the intracerebroventricular injection of astressin (68). However, its effect on the colon motility is the opposite, stimulating the movement and contributing to the process of colitis (68) (see below 1.1.2).

2.1.2 The pro-inflammatory effect of central CRH in colitis as a stress mediator

Compiling evidences show that central CRH plays indirectly a proinflammatory role in colitis. HPA axis is the critical pathway of stress response, which is elicited by physical or psychological stimuli (stressors). A stress response involves activation of sympathetic-adreno-medullar (SAM) axis, HPA axis, and immune system, and a prolonged stressor exposure constitutes a chronic stress (69).

Chronic stress is known to promote IBD (64, 69), but the underlying mechanism remains largely unresolved. IBD is a model of microbial, immune and neuropsychological integration (70, 71). It is reported that chronic stress sensitizes mice to dextran sulfate sodium (DSS)-induced colitis and enhances the infiltration of proinflammatory cells in colonic lamina propria (72). Also, a marked increase in IL-6, a stress-inducible cytokine that further activates HPA axis in a positive feedback manner, is observed (73). Moreover, IBD is presumed to be a disorder of the brain–gut-microbiome link associated with exaggerated response to stress (74, 75). Under stress, inflammation-promoting bacteria expand while transferred gut microbiota from stressed mice facilitate DSS-induced colitis, which is abrogated by broad-spectrum antibiotic treatment (72). Therefore, it is obvious that chronic stress leads to colitis via disturbing gut microbiota and hence triggering immune system response. Based on these reports, CRH, as the main stress mediator, is evidently a critical factor in the development of colitis.

Interestingly, researchers record colonic motility and reveal that restraint stress, or intracerebroventricular injections of CRH, produce significant increases in colonic motility although CRH inhibits gastric motility (68, 76), which contributes to the occurrence of abdominal pain during IBD. Central injection of astressin is observed to block exogenous CRH action and colonic response to stress, showing an antagonistic action against CRH and stress-related alterations of gastrointestinal motor function, without an intrinsic effect in rats (68). Moreover, it is observed that the colonic contractions induced by central CRH are eliminated by intracerebroventricular pretreatment with astressin (76). On the other hand, peripherally administered CRH partially mimics the stress response of the gastrointestinal motility, exaggerated in IBD patients (77), further suggesting that CRH plays an important role in modulating brain-gut functions under stress.

CRH is also found to participate in IBD during acute stress. Zhao et al. establishes a model of psychosocial stress by peripheral administration of CRH and find that CRH aggravates DSS-induced colitis via the enhancement of intestinal macrophage autophagy (78). It is observed that peripherally used CRH aggravates the severity of DSS-induced IBD, increasing overall and local inflammatory reactions and infiltration. Under the IBD-related inflammatory challenges, the autophagy levels in intestinal macrophages are significantly increased, which is further enhanced by CRH. The autophagy inhibitor, chloroquine, markedly attenuates the detrimental effects of CRH reducing the severity and inflammatory reactions (78). These results may suggest that CRH, while working centrally mimicking stress, simultaneously exacerbates DSS-induced IBD via enhancing intestinal macrophage autophagy. Therefore, it is reasonable to believe that CRH and related receptors may be a potential therapeutic target for the treatment of IBD. Another investigation also shows that peripherally administered CRH mimic the effect of acute psychological stress, leading to increased intestinal permeability characterized in IBD (79). These findings further provide new insights into the complex interplay between the central and peripheral role of CRH in IBD since CRH is administered peripherally for stress model.

2.2 Central role of CRH in colitis-associated colon cancer

Rare evidence shows a direct relationship between the central CRH and the development of cancers. However, the relationship between chronic stress and tumor development has been frequently reported and widely reviewed (38–41, 80, 81). Therefore, it is believable that the central role of CRH in tumor is likewise mainly via the indirect way through HPA axis-mediated stress.

Clinically, chronic stress is found common among cancer patients due to stressors encountered (82). Primarily, chronic stress activates the classic neuroendocrine systems, the HPA axis and the SAM, whose continuous activations have been demonstrated to take part in cancer-promoting processes by altering the tumor microenvironment (TME) (39, 81, 83). Stress hormones can promote colon cancer development through a variety of mechanisms: 1) Corresponding changes in the body’s immune function and inflammatory response (40, 83, 84); 2) Significant influence on the gut flora, i.e. the brain-gut-microbiota axis, promoting the composition of pro-inflammatory microbiome and hence resulting in colitis leading to CAC (85, 86).

Although the mechanisms might be complicated, it is believable that the central CRH, the upper element of HPA axis and stress mediator, plays a role in CAC based on that central CRH participates in colitis (see 2.1) and the cross talks between inflammation/immunity and cancer (87, 88). Recently, the microbiota has been recognized as one of the key regulators of gut-brain function. Many factors, stress in particular, can influence microbiota composition (89). Importantly, dysbiosis of the gut microbiome is found to be associated with the development of colorectal cancer (90) (see below 2.2). As precedingly described, individuals having IBD develop more easily into CAC (7, 57), and gut microbiome is involved in colon inflammation and biosynthesis of chemical carcinogens such as N-nitroso compounds that drive carcinogenesis (90–92). Meta-analysis demonstrates that in patients under stress gut microbiota perturbations are associated with loss of certain anti-inflammatory bacteria but an enrichment of pro-inflammatory bacteria (89), suggesting an interaction between the central CRH and gut flora.

It is nowadays recognized that dietary mode is related to colon microbiota (92, 93), leading to the idea that modulating the growth of beneficial microbiota in the gut by dietary and life style interventions may be a useful approach for prevention of colon cancer (94, 95). Based on the importance of the brain-gut-microbe axis during chronic stress, interfering chronic stress using CRH-related drugs might also become a useful approach for CAC prevention and treatment.

3 Peripheral roles of CRH in colitis and CAC

As precedingly described, although CRH is first isolated in CNS where it is initially recognized to be the main target site, CRH and the other CRF peptides have then been observed existing and functioning peripherally. Furthermore, the two receptors, CRF1 and CRF2 have been detected in many types of peripheral cells/tissues, such as immune cells, endothelial cells, tumor cells, etc. (13, 28, 42). CRH and the other CRF peptides are revealed to have a variety of direct peripheral functions in cardiovascular system, gastrointestinal system and immune system (13, 42). Besides the centrally indirect influence via mediating stress, CRH is also reported by our group and others to play a direct peripheral role in inflammation and tumors, including colitis and CAC (13, 42, 43, 50, 57, 58).

3.1 Peripheral participation of CRH in colitis

CRH & UCNs and the receptors are observed to be closely related to gastrointestinal system (12, 13, 96, 97) and reported to be implicated in colitis (43, 98, 99).

Firstly, CRH, the selective CRF1 ligand/agonist, is reported to play a significant role in the gastrointestinal motility by stimulating enteric nervous system (100) and evidence supporting that peripheral CRH & CRF1 directly take part in brain-gut sensitization is increasing (43). As mentioned above, IBD displays chronic abdominal pain or discomfort due to altered gut motility and visceral sensation (1, 100). Moreover, peripheral injection of CRH or UCN1 inhibits human gastric emptying and motility through interaction with CRF2, but stimulates colonic motility through activation of CRF1 (101). CRH induces motility of the descending colon in both healthy subjects and colitis patients, the latter with greater motility indexes. Paralally, abdominal symptoms evoked by CRH in colitis patients last significantly longer than in healthy controls (101). Moreover, rectal electric stimulation-induced significantly higher motility indices of the colon in colitis patients (vs healthy controls) are suppressed after administration of the selective antagonist of CRH, alphahCRH (αhCRH). Consistently, αhCRH significantly reduces the ordinate scale of abdominal pain evoked by the electric stimulation in colitis patients without changing ACTH and serum cortisol levels (102). Interestingly, peripheral administration of CRH is observed to aggravate visceral sensorimotor function as well as ACTH response in IBD patients (43, 100, 103). However, αhCRH is found to suppress higher motility among IBD patients, reducing the abdominal pain without plasma ACTH & cortisol change (43), suggesting the dominant peripheral effect. Furthermore, αhCRH is observed to block colorectal distention-induced sensitization of the visceral perception in rats (43, 102, 104). All these results demonstrate that besides its central action, CRH/CRF1 enhances colon motility, contributing to abdominal pain peripherally.

Secondly, peripheral CRH may play a role in colitis via influencing immune/inflammatory processes (42). Our group find that expressions of UCN1 and CRH are enhanced in the colon of wild type (Crhr1+/+) mice during azoxymethane (AOM) and DSS treatment (57). CRF1 has a proinflammatory and therefore a carcinogenetic (see below) effect in the mouse colon. The extent and severity of inflammation are drastically decreased in Crhr1-/- mice with much lower inflammatory cytokines’ expression, grade of dysplasia and numbers of ulceration in the colon mucosa. Moreover, accompanying the markedly lower proinflammatory cytokines, IL-1, IL-6, and TNF-α, the anti-inflammatory factor, IL-10 is increased in Crhr1-/- mice. Our results are consistent with the reports that CRF1 activation promotes inflammation (13, 42, 50, 103). However, in case of innate immunity deficiency, the opposite effect of CRH/CRF1 is observed (98). Chaniotou group investigate the role of CRH in an innate immunity–dependent mouse model of IBD (98). CRH-/- mice are observed to have more colonic inflammation than CRH+/+ mice in DDS-induced colitis model. Moreover, as precedingly described, it is observed that, CRH further enhances the promoted autophagy levels in intestinal macrophages in IBD patients, which is markedly attenuated by the autophagy inhibitor, chloroquine, reducing CRH-induced severity and inflammatory reactions (76). These results may suggest that CRH, while working centrally mimicking stress, simultaneously exacerbates DSS-induced IBD via enhancing intestinal macrophage autophagy. Therefore, it is reasonable to believe that CRH and related receptors may be a potential therapeutic target for the treatment of IBD. In addition, mast cells are found to be related to CRH effects participating in the process of colitis, increasing the intestinal mucosal permeability (101).

The role of CRF2 in colitis is also complicated. It is reported that CRF2 has a counter regulatory action against CRF1, maintaining a balance between CRF1 and CRF2 during inflammation (103). On one hand, CRF2 is observed to function as a proinflammatory element while on the other hand, it displays an anti-inflammatory feature (105). Activation of CRF2 is reported to promote inflammation during acute colitis but to inhibit inflammation during chronic colitis (106). In DSS-induced colitis, mucosal repair is delayed after administration of a CRF2 antagonist (106). Moreover, CRF2 is down-regulated in human colitis (107). Taken together, a balance between CRF1 and CRF2 may decide the process of inflammation (103). This balance-theory may well interpret that both CRF1 and CRF2 are found to participate in acute inflammation while CRF2 is the main type for repair (103). The theory may lead to better understanding the pathophysiology and provide novel therapeutic options targeting altered signaling balance of CRF1 and CRF2 in IBD.

3.2 Peripheral CRH’s role in colitis-associated colon cancer

CRH is present in the colonic mucosa of UC patients and acts as a proinflammatory factor modulating the intestinal immune system (29, 47). Furthermore, UCN1, the unselective agonist for CRF1 and CRF2, is found to be synthesized and secreted in plasma cells, related to the inflammation in colonic mucosa (108). In addition, in DSS-induced mouse colitis, CRF1 deficiency is observed to contribute to the relief of colon inflammation (57). These reports suggest that direct activation of CRF1 exerts an effect of exacerbating colitis and hence may promote CAC. Up-to-date, only a few experimental reports have been presented on the direct peripheral role of CRH & UCNs in CAC.

In 2014, we first investigate the functions of CRF1 signaling on the development of CAC by using CRF1 deficient mice in AOM and DSS-induced CAC model. And the results show that in WT (Crhr1+/+) mice, CRF1 and its endogenous ligands (UCN1 and CRH) are significantly enhanced in the colon during AOM and DSS treatment. Interestingly, in Crhr1-/- mice, tumorigenesis is dramatically reduced, accompanied by lower inflammatory responses, i.e., decreased IL-1β, IL-6, TNF-α level and macrophage infiltration. Moreover, a reduced activation of NF-κB and STAT3 phosphorylation, together with decreased proliferating & enhanced apoptotic cells in the colon are observed (57). The pro-tumorigenesis effect is further confirmed by our in vitro experiments (58). CRH enhances colon cancer cell proliferation, promoting colony formation. Furthermore, tube formation assay shows that CRH treatment significantly promotes angiogenesis of HUVECs. Further investigation shows that CRH/CRF1 significantly upregulates IL-6 and VEGF level through activating NF-κB. And the VEGF silence abolishes the tube formation induced by CRH. The CRH-induced IL-6 promotes STAT3 phosphorylation, whose inhibition by Stattic significantly inhibits the CRH-induced cell proliferation (58). Our data is consistent with a newly reported experiment, demonstrating that CRF1 deficiency inhibits CRC in AOM/DSS model (56). Taken together, CRH/CRF1 signaling promotes human colon cancer cell proliferation via NF-κB/IL-6/STAT3 and tumor angiogenesis via NF-κB/VEGF signaling pathway. Our results provide evidence to support a critical role for the CRH/CRF1 signaling in colon cancer progression and suggest its potential utility as a new therapeutic target for CAC. Based on the above, it is believable that CRH/CRF1 has a proinflammatory and therefore a pro-tumorigenic effect in terms of CAC, which might be a direction for developing new therapeutic approaches for inflammation and CAC prevention & treatment.

It is observed by Baritaki group that human colon tissues from CRC patients and CRC cell lines show decreased CRF2 expression (109). Contrary to CRH/CRF1, UCN2/CRF2 signaling inhibits cell proliferation, migration, invasion and colony formation. Furthermore, IL-1β, IL-6 and IL-6R mRNAs are diminished in CRC-CRF2+ cells. In CRC patients’ colon samples, CRF2 mRNA expression is inversely correlated with IL-6R (109). These results are in concert with the report that CRF2 deficiency worsens CRC in AOM/DSS model (56). However, opposite effect of CRF2 is also reported, i.e. CRF2 may promote the development of CRC (110). Also, a blood sample analysis suggests that CRF2 represent a risk factor for CRC development in Mexican patients (111), which raises a controversial question as well. Recently, researchers have reported the methylation status of both CRF1 and CRF2, and point out that this examination may become a promising screening approach for CAC (112, 113).

In addition, it is well established that there exists a link between gut microbiota and colitis & colon cancer (87, 114–116). As precedingly described, CRH exerts an effect on gut flora mainly as a central stress mediator via brain-gut axis. However, up-to-date, rare experimental evidence shows direct peripheral effects of CRH on gut flora.

4 Summary

Emerging evidence suggests that uncontrolled inflammation is a major risk factor for the development of cancer. A typical example for inflammation and inflammation-based tumor is colitis and CAC, strongly supported by the fact that patients with UC have a much higher risk for CAC. This review aims to mainly summarize the reports about CRH’ roles in the development of colitis and CAC, both central and peripheral, hoping to be helpful in giving a clue to future drug design of CRH relevance, as having been studied (55).

As summarized in Figure 1, CRH, as the main stress mediator, may participate in colitis and CAC via CRF1 as a central factor. Meanwhile, CRH and UCNs have been proved to play an important role in the development of colitis and CAC peripherally in which CRF1 may dominantly function as a pro-inflammatory and pro-tumorigenesis element while CRF2 may do oppositely. However, there exists no clearcut between CRH’s central and peripheral effects in colitis and CAC because of cross-talks between HPA axis and the immune system, and also between central and myenteric neurons.

Figure 1 The role of CRH in colitis and CAC.

However, there still lack experimental evidences for a direct relationship between central CRH and colitis/CAC, while there are also relatively few investigations on CRH’s peripheral effects on CAC. Given that CRH has a crucial role in stress and gastrointestinal system, with further evidence-reveal in the future, CRH may become a promising therapeutic target for colitis and CAC.

Author contributions

CZ: Writing – original draft, Writing – review & editing. SL: Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China No. 81773724 & 82273918.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

3. Meynier M, Baudu E, Rolhion N, Defaye M, Straube M, Daugey V, et al. AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms. Gut Microbes. (2022) 14:2022997. doi: 10.1080/19490976.2021.2022997

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Olen O, Erichsen R, Sachs MC, Pedersen L, Halfvarson J, Askling J, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet. (2020) 395:123–31. doi: 10.1016/S0140-6736(19)32545-0

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Suh SS, Hong JM, Kim EJ, Jung SW, Kim SM, Kim JE, et al. Anti-inflammation and anti-cancer activity of ethanol extract of antarctic freshwater microalga, micractinium sp. Int J Med Sci. (2018) 15:929–36. doi: 10.7150/ijms.26410

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Jahanafrooz Z, Mosafer J, Akbari M, Hashemzaei M, Mokhtarzadeh A, Baradaran B. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. J Cell Physiol. (2020) 235:4153–66. doi: 10.1002/jcp.29337

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Chen R, Lewis KA, Perrin MH, Vale WW. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U.S.A. (1993) 90:8967–71. doi: 10.1073/pnas.90.19.8967

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Chang CP, Pearse RV 2nd, O'Connell S, Rosenfeld MG. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron. (1993) 11:1187–95. doi: 10.1016/0896-6273(93)90230-O